Biologics and Biosimilars Market Size, Share, Value and Forecast 2034
Biologics and Biosimilars Market By Drug Class (Vaccines, Monoclonal Antibodies, Recombinant Insulin, Fusion Protein, Growth Factors, Interferons, Erythropoietin, Immune Modulators, Oligonucleotides, Colony Stimulation Factors, and Others), By Source (Animal Cells, Plant Cells, Bacterial Cells, Yeast Cells, and Others), By Application (Autoimmune Diseases, Oncology, Rare Diseases, Infectious Diseases, Hematological Disorders, Cardiovascular Diseases, and Others), By Manufacturing Type (Contract Manufacturing, In-House Manufacturing, and Hybrid Manufacturing), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Specialty Pharmacies), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2026 - 2034
Category: Pharmaceutical Report Format : PDF
Pages: 228 Report Code: ZMR-10809
Published Date: Oct-2026 Status : Published
| Market Size in 2025 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 527.36 Billion | USD 1320.19 Billion | 10.77% | 2025 |
Table Of Content
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market research methodology
- Chapter 2. Executive Summary
- 2.1 Global Biologics and Biosimilars Market, (2026 - 2034) (USD Billion)
- 2.2 Global Biologics and Biosimilars Market : snapshot
- Chapter 3. Global Biologics and Biosimilars Market - Industry Analysis
- 3.1 Biologics and Biosimilars Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Surge in patients with autoimmune diseases to drive market revenue in the long run
- 3.3 Market Restraints
- 3.3.1. Cost the leading growth barrier in the biologics and biosimilars industry
- 3.4 Market Opportunities
- 3.4.1. Ongoing advancements support expansion of the biologics and biosimilars market
- 3.5 Market Challenges
- 3.5.1. Intellectual property-related barriers and lack of infrastructure to challenge industry growth
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market attractiveness analysis By Drug Class
- 3.7.2 Market attractiveness analysis By Source
- 3.7.3 Market attractiveness analysis By Application
- 3.7.4 Market attractiveness analysis By Manufacturing Type
- 3.7.5 Market attractiveness analysis By Distribution Channel
- Chapter 4. Global Biologics and Biosimilars Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Biologics and Biosimilars Market: company market share, 2025
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Biologics and Biosimilars Market - Drug Class Analysis
- 5.1 Global Biologics and Biosimilars Market overview: By Drug Class
- 5.1.1 Global Biologics and Biosimilars Market share, By Drug Class, 2025 and 2034
- 5.2 Vaccines
- 5.2.1 Global Biologics and Biosimilars Market by Vaccines, 2026 - 2034 (USD Billion)
- 5.3 Monoclonal Antibodies
- 5.3.1 Global Biologics and Biosimilars Market by Monoclonal Antibodies, 2026 - 2034 (USD Billion)
- 5.4 Recombinant Insulin
- 5.4.1 Global Biologics and Biosimilars Market by Recombinant Insulin, 2026 - 2034 (USD Billion)
- 5.5 Fusion Protein
- 5.5.1 Global Biologics and Biosimilars Market by Fusion Protein, 2026 - 2034 (USD Billion)
- 5.6 Growth Factors
- 5.6.1 Global Biologics and Biosimilars Market by Growth Factors, 2026 - 2034 (USD Billion)
- 5.7 Interferons
- 5.7.1 Global Biologics and Biosimilars Market by Interferons, 2026 - 2034 (USD Billion)
- 5.8 Erythropoietin
- 5.8.1 Global Biologics and Biosimilars Market by Erythropoietin, 2026 - 2034 (USD Billion)
- 5.9 Immune Modulators
- 5.9.1 Global Biologics and Biosimilars Market by Immune Modulators, 2026 - 2034 (USD Billion)
- 5.10 Oligonucleotides
- 5.10.1 Global Biologics and Biosimilars Market by Oligonucleotides, 2026 - 2034 (USD Billion)
- 5.11 Colony Stimulation Factors
- 5.11.1 Global Biologics and Biosimilars Market by Colony Stimulation Factors, 2026 - 2034 (USD Billion)
- 5.12 Others
- 5.12.1 Global Biologics and Biosimilars Market by Others, 2026 - 2034 (USD Billion)
- 5.1 Global Biologics and Biosimilars Market overview: By Drug Class
- Chapter 6. Global Biologics and Biosimilars Market - Source Analysis
- 6.1 Global Biologics and Biosimilars Market overview: By Source
- 6.1.1 Global Biologics and Biosimilars Market share, By Source, 2025 and 2034
- 6.2 Source
- 6.2.1 Global Biologics and Biosimilars Market by Source, 2026 - 2034 (USD Billion)
- 6.3 Animal Cells
- 6.3.1 Global Biologics and Biosimilars Market by Animal Cells, 2026 - 2034 (USD Billion)
- 6.4 Plant Cells
- 6.4.1 Global Biologics and Biosimilars Market by Plant Cells, 2026 - 2034 (USD Billion)
- 6.5 Bacterial Cells
- 6.5.1 Global Biologics and Biosimilars Market by Bacterial Cells, 2026 - 2034 (USD Billion)
- 6.6 Yeast Cells
- 6.6.1 Global Biologics and Biosimilars Market by Yeast Cells, 2026 - 2034 (USD Billion)
- 6.7 Others
- 6.7.1 Global Biologics and Biosimilars Market by Others, 2026 - 2034 (USD Billion)
- 6.1 Global Biologics and Biosimilars Market overview: By Source
- Chapter 7. Global Biologics and Biosimilars Market - Application Analysis
- 7.1 Global Biologics and Biosimilars Market overview: By Application
- 7.1.1 Global Biologics and Biosimilars Market share, By Application, 2025 and 2034
- 7.2 Autoimmune Diseases
- 7.2.1 Global Biologics and Biosimilars Market by Autoimmune Diseases, 2026 - 2034 (USD Billion)
- 7.3 Oncology
- 7.3.1 Global Biologics and Biosimilars Market by Oncology, 2026 - 2034 (USD Billion)
- 7.4 Rare Diseases
- 7.4.1 Global Biologics and Biosimilars Market by Rare Diseases, 2026 - 2034 (USD Billion)
- 7.5 Infectious Diseases
- 7.5.1 Global Biologics and Biosimilars Market by Infectious Diseases, 2026 - 2034 (USD Billion)
- 7.6 Hematological Disorders
- 7.6.1 Global Biologics and Biosimilars Market by Hematological Disorders, 2026 - 2034 (USD Billion)
- 7.7 Cardiovascular Diseases
- 7.7.1 Global Biologics and Biosimilars Market by Cardiovascular Diseases, 2026 - 2034 (USD Billion)
- 7.8 Others
- 7.8.1 Global Biologics and Biosimilars Market by Others, 2026 - 2034 (USD Billion)
- 7.1 Global Biologics and Biosimilars Market overview: By Application
- Chapter 8. Global Biologics and Biosimilars Market - Manufacturing Type Analysis
- 8.1 Global Biologics and Biosimilars Market overview: By Manufacturing Type
- 8.1.1 Global Biologics and Biosimilars Market share, By Manufacturing Type, 2025 and 2034
- 8.2 Contract Manufacturing
- 8.2.1 Global Biologics and Biosimilars Market by Contract Manufacturing, 2026 - 2034 (USD Billion)
- 8.3 In-House Manufacturing
- 8.3.1 Global Biologics and Biosimilars Market by In-House Manufacturing, 2026 - 2034 (USD Billion)
- 8.4 Hybrid Manufacturing
- 8.4.1 Global Biologics and Biosimilars Market by Hybrid Manufacturing, 2026 - 2034 (USD Billion)
- 8.1 Global Biologics and Biosimilars Market overview: By Manufacturing Type
- Chapter 9. Global Biologics and Biosimilars Market - Distribution Channel Analysis
- 9.1 Global Biologics and Biosimilars Market overview: By Distribution Channel
- 9.1.1 Global Biologics and Biosimilars Market share, By Distribution Channel, 2025 and 2034
- 9.2 Retail Pharmacies
- 9.2.1 Global Biologics and Biosimilars Market by Retail Pharmacies, 2026 - 2034 (USD Billion)
- 9.3 Hospital Pharmacies
- 9.3.1 Global Biologics and Biosimilars Market by Hospital Pharmacies, 2026 - 2034 (USD Billion)
- 9.4 Online Pharmacies
- 9.4.1 Global Biologics and Biosimilars Market by Online Pharmacies, 2026 - 2034 (USD Billion)
- 9.5 Specialty Pharmacies
- 9.5.1 Global Biologics and Biosimilars Market by Specialty Pharmacies, 2026 - 2034 (USD Billion)
- 9.1 Global Biologics and Biosimilars Market overview: By Distribution Channel
- Chapter 10. Biologics and Biosimilars Market - Regional Analysis
- 10.1 Global Biologics and Biosimilars Market Regional Overview
- 10.2 Global Biologics and Biosimilars Market Share, by Region, 2025 & 2034 (USD Billion)
- 10.3. North America
- 10.3.1 North America Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 10.3.1.1 North America Biologics and Biosimilars Market, by Country, 2026 - 2034 (USD Billion)
- 10.3.1 North America Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 10.4 North America Biologics and Biosimilars Market, by Drug Class, 2026 - 2034
- 10.4.1 North America Biologics and Biosimilars Market, by Drug Class, 2026 - 2034 (USD Billion)
- 10.5 North America Biologics and Biosimilars Market, by Source, 2026 - 2034
- 10.5.1 North America Biologics and Biosimilars Market, by Source, 2026 - 2034 (USD Billion)
- 10.6 North America Biologics and Biosimilars Market, by Application, 2026 - 2034
- 10.6.1 North America Biologics and Biosimilars Market, by Application, 2026 - 2034 (USD Billion)
- 10.7 North America Biologics and Biosimilars Market, by Manufacturing Type, 2026 - 2034
- 10.7.1 North America Biologics and Biosimilars Market, by Manufacturing Type, 2026 - 2034 (USD Billion)
- 10.8 North America Biologics and Biosimilars Market, by Distribution Channel, 2026 - 2034
- 10.8.1 North America Biologics and Biosimilars Market, by Distribution Channel, 2026 - 2034 (USD Billion)
- 10.4. Europe
- 10.4.2 Europe Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 10.4.2.1 Europe Biologics and Biosimilars Market, by Country, 2026 - 2034 (USD Billion)
- 10.4.2 Europe Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 10.4 Europe Biologics and Biosimilars Market, by Drug Class, 2026 - 2034
- 10.4.1 Europe Biologics and Biosimilars Market, by Drug Class, 2026 - 2034 (USD Billion)
- 10.5 Europe Biologics and Biosimilars Market, by Source, 2026 - 2034
- 10.5.1 Europe Biologics and Biosimilars Market, by Source, 2026 - 2034 (USD Billion)
- 10.6 Europe Biologics and Biosimilars Market, by Application, 2026 - 2034
- 10.6.1 Europe Biologics and Biosimilars Market, by Application, 2026 - 2034 (USD Billion)
- 10.7 Europe Biologics and Biosimilars Market, by Manufacturing Type, 2026 - 2034
- 10.7.1 Europe Biologics and Biosimilars Market, by Manufacturing Type, 2026 - 2034 (USD Billion)
- 10.8 Europe Biologics and Biosimilars Market, by Distribution Channel, 2026 - 2034
- 10.8.1 Europe Biologics and Biosimilars Market, by Distribution Channel, 2026 - 2034 (USD Billion)
- 10.5. Asia Pacific
- 10.5.3 Asia Pacific Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 10.5.3.1 Asia Pacific Biologics and Biosimilars Market, by Country, 2026 - 2034 (USD Billion)
- 10.5.3 Asia Pacific Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 10.4 Asia Pacific Biologics and Biosimilars Market, by Drug Class, 2026 - 2034
- 10.4.1 Asia Pacific Biologics and Biosimilars Market, by Drug Class, 2026 - 2034 (USD Billion)
- 10.5 Asia Pacific Biologics and Biosimilars Market, by Source, 2026 - 2034
- 10.5.1 Asia Pacific Biologics and Biosimilars Market, by Source, 2026 - 2034 (USD Billion)
- 10.6 Asia Pacific Biologics and Biosimilars Market, by Application, 2026 - 2034
- 10.6.1 Asia Pacific Biologics and Biosimilars Market, by Application, 2026 - 2034 (USD Billion)
- 10.7 Asia Pacific Biologics and Biosimilars Market, by Manufacturing Type, 2026 - 2034
- 10.7.1 Asia Pacific Biologics and Biosimilars Market, by Manufacturing Type, 2026 - 2034 (USD Billion)
- 10.8 Asia Pacific Biologics and Biosimilars Market, by Distribution Channel, 2026 - 2034
- 10.8.1 Asia Pacific Biologics and Biosimilars Market, by Distribution Channel, 2026 - 2034 (USD Billion)
- 10.6. Latin America
- 10.6.4 Latin America Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 10.6.4.1 Latin America Biologics and Biosimilars Market, by Country, 2026 - 2034 (USD Billion)
- 10.6.4 Latin America Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 10.4 Latin America Biologics and Biosimilars Market, by Drug Class, 2026 - 2034
- 10.4.1 Latin America Biologics and Biosimilars Market, by Drug Class, 2026 - 2034 (USD Billion)
- 10.5 Latin America Biologics and Biosimilars Market, by Source, 2026 - 2034
- 10.5.1 Latin America Biologics and Biosimilars Market, by Source, 2026 - 2034 (USD Billion)
- 10.6 Latin America Biologics and Biosimilars Market, by Application, 2026 - 2034
- 10.6.1 Latin America Biologics and Biosimilars Market, by Application, 2026 - 2034 (USD Billion)
- 10.7 Latin America Biologics and Biosimilars Market, by Manufacturing Type, 2026 - 2034
- 10.7.1 Latin America Biologics and Biosimilars Market, by Manufacturing Type, 2026 - 2034 (USD Billion)
- 10.8 Latin America Biologics and Biosimilars Market, by Distribution Channel, 2026 - 2034
- 10.8.1 Latin America Biologics and Biosimilars Market, by Distribution Channel, 2026 - 2034 (USD Billion)
- 10.7. The Middle-East and Africa
- 10.7.5 The Middle-East and Africa Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 10.7.5.1 The Middle-East and Africa Biologics and Biosimilars Market, by Country, 2026 - 2034 (USD Billion)
- 10.7.5 The Middle-East and Africa Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 10.4 The Middle-East and Africa Biologics and Biosimilars Market, by Drug Class, 2026 - 2034
- 10.4.1 The Middle-East and Africa Biologics and Biosimilars Market, by Drug Class, 2026 - 2034 (USD Billion)
- 10.5 The Middle-East and Africa Biologics and Biosimilars Market, by Source, 2026 - 2034
- 10.5.1 The Middle-East and Africa Biologics and Biosimilars Market, by Source, 2026 - 2034 (USD Billion)
- 10.6 The Middle-East and Africa Biologics and Biosimilars Market, by Application, 2026 - 2034
- 10.6.1 The Middle-East and Africa Biologics and Biosimilars Market, by Application, 2026 - 2034 (USD Billion)
- 10.7 The Middle-East and Africa Biologics and Biosimilars Market, by Manufacturing Type, 2026 - 2034
- 10.7.1 The Middle-East and Africa Biologics and Biosimilars Market, by Manufacturing Type, 2026 - 2034 (USD Billion)
- 10.8 The Middle-East and Africa Biologics and Biosimilars Market, by Distribution Channel, 2026 - 2034
- 10.8.1 The Middle-East and Africa Biologics and Biosimilars Market, by Distribution Channel, 2026 - 2034 (USD Billion)
- Chapter 11. Company Profiles
- 11.1 Roche
- 11.1.1 Overview
- 11.1.2 Financials
- 11.1.3 Product Portfolio
- 11.1.4 Business Strategy
- 11.1.5 Recent Developments
- 11.2 Fresenius Kabi
- 11.2.1 Overview
- 11.2.2 Financials
- 11.2.3 Product Portfolio
- 11.2.4 Business Strategy
- 11.2.5 Recent Developments
- 11.3 Biocon Biologics
- 11.3.1 Overview
- 11.3.2 Financials
- 11.3.3 Product Portfolio
- 11.3.4 Business Strategy
- 11.3.5 Recent Developments
- 11.4 Johnson & Johnson
- 11.4.1 Overview
- 11.4.2 Financials
- 11.4.3 Product Portfolio
- 11.4.4 Business Strategy
- 11.4.5 Recent Developments
- 11.5 Amgen
- 11.5.1 Overview
- 11.5.2 Financials
- 11.5.3 Product Portfolio
- 11.5.4 Business Strategy
- 11.5.5 Recent Developments
- 11.6 Merck & Co.
- 11.6.1 Overview
- 11.6.2 Financials
- 11.6.3 Product Portfolio
- 11.6.4 Business Strategy
- 11.6.5 Recent Developments
- 11.7 Samsung Bioepis
- 11.7.1 Overview
- 11.7.2 Financials
- 11.7.3 Product Portfolio
- 11.7.4 Business Strategy
- 11.7.5 Recent Developments
- 11.8 Pfizer
- 11.8.1 Overview
- 11.8.2 Financials
- 11.8.3 Product Portfolio
- 11.8.4 Business Strategy
- 11.8.5 Recent Developments
- 11.9 Teva Pharmaceuticals
- 11.9.1 Overview
- 11.9.2 Financials
- 11.9.3 Product Portfolio
- 11.9.4 Business Strategy
- 11.9.5 Recent Developments
- 11.10 AbbVie
- 11.10.1 Overview
- 11.10.2 Financials
- 11.10.3 Product Portfolio
- 11.10.4 Business Strategy
- 11.10.5 Recent Developments
- 11.11 Celltrion
- 11.11.1 Overview
- 11.11.2 Financials
- 11.11.3 Product Portfolio
- 11.11.4 Business Strategy
- 11.11.5 Recent Developments
- 11.12 Eli Lilly
- 11.12.1 Overview
- 11.12.2 Financials
- 11.12.3 Product Portfolio
- 11.12.4 Business Strategy
- 11.12.5 Recent Developments
- 11.13 Sanofi
- 11.13.1 Overview
- 11.13.2 Financials
- 11.13.3 Product Portfolio
- 11.13.4 Business Strategy
- 11.13.5 Recent Developments
- 11.14 Sandoz
- 11.14.1 Overview
- 11.14.2 Financials
- 11.14.3 Product Portfolio
- 11.14.4 Business Strategy
- 11.14.5 Recent Developments
- 11.15 Biogen
- 11.15.1 Overview
- 11.15.2 Financials
- 11.15.3 Product Portfolio
- 11.15.4 Business Strategy
- 11.15.5 Recent Developments
- 11.16 and others.
- 11.16.1 Overview
- 11.16.2 Financials
- 11.16.3 Product Portfolio
- 11.16.4 Business Strategy
- 11.16.5 Recent Developments
- 11.1 Roche
Table Of Figures
- 1. Market research Type
- 2. Market research methodology
- 3. Global Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 4. Porter’s Five Forces Analysis
- 5. Global Biologics and Biosimilars Market attractiveness, By Drug Class
- 6. Global Biologics and Biosimilars Market attractiveness, By Source
- 7. Global Biologics and Biosimilars Market attractiveness, By Application
- 8. Global Biologics and Biosimilars Market attractiveness, By Manufacturing Type
- 9. Global Biologics and Biosimilars Market attractiveness, By Distribution Channel
- 10. Global Biologics and Biosimilars Market share by Drug Class, 2026 and 2034 (USD Billion)
- 11. Global Biologics and Biosimilars Market by Vaccines, 2026 - 2034 (USD Billion)
- 12. Global Biologics and Biosimilars Market by Monoclonal Antibodies, 2026 - 2034 (USD Billion)
- 13. Global Biologics and Biosimilars Market by Recombinant Insulin, 2026 - 2034 (USD Billion)
- 14. Global Biologics and Biosimilars Market by Fusion Protein, 2026 - 2034 (USD Billion)
- 15. Global Biologics and Biosimilars Market by Growth Factors, 2026 - 2034 (USD Billion)
- 16. Global Biologics and Biosimilars Market by Interferons, 2026 - 2034 (USD Billion)
- 17. Global Biologics and Biosimilars Market by Erythropoietin, 2026 - 2034 (USD Billion)
- 18. Global Biologics and Biosimilars Market by Immune Modulators, 2026 - 2034 (USD Billion)
- 19. Global Biologics and Biosimilars Market by Oligonucleotides, 2026 - 2034 (USD Billion)
- 20. Global Biologics and Biosimilars Market by Colony Stimulation Factors, 2026 - 2034 (USD Billion)
- 21. Global Biologics and Biosimilars Market by Others, 2026 - 2034 (USD Billion)
- 22. Global Biologics and Biosimilars Market share by Source, 2026 and 2034 (USD Billion)
- 23. Global Biologics and Biosimilars Market by Source, 2026 - 2034 (USD Billion)
- 24. Global Biologics and Biosimilars Market by Animal Cells, 2026 - 2034 (USD Billion)
- 25. Global Biologics and Biosimilars Market by Plant Cells, 2026 - 2034 (USD Billion)
- 26. Global Biologics and Biosimilars Market by Bacterial Cells, 2026 - 2034 (USD Billion)
- 27. Global Biologics and Biosimilars Market by Yeast Cells, 2026 - 2034 (USD Billion)
- 28. Global Biologics and Biosimilars Market by Others, 2026 - 2034 (USD Billion)
- 29. Global Biologics and Biosimilars Market share by Application, 2026 and 2034 (USD Billion)
- 30. Global Biologics and Biosimilars Market by Autoimmune Diseases, 2026 - 2034 (USD Billion)
- 31. Global Biologics and Biosimilars Market by Oncology, 2026 - 2034 (USD Billion)
- 32. Global Biologics and Biosimilars Market by Rare Diseases, 2026 - 2034 (USD Billion)
- 33. Global Biologics and Biosimilars Market by Infectious Diseases, 2026 - 2034 (USD Billion)
- 34. Global Biologics and Biosimilars Market by Hematological Disorders, 2026 - 2034 (USD Billion)
- 35. Global Biologics and Biosimilars Market by Cardiovascular Diseases, 2026 - 2034 (USD Billion)
- 36. Global Biologics and Biosimilars Market by Others, 2026 - 2034 (USD Billion)
- 37. Global Biologics and Biosimilars Market share by Manufacturing Type, 2026 and 2034 (USD Billion)
- 38. Global Biologics and Biosimilars Market by Contract Manufacturing, 2026 - 2034 (USD Billion)
- 39. Global Biologics and Biosimilars Market by In-House Manufacturing, 2026 - 2034 (USD Billion)
- 40. Global Biologics and Biosimilars Market by Hybrid Manufacturing, 2026 - 2034 (USD Billion)
- 41. Global Biologics and Biosimilars Market share by Distribution Channel, 2026 and 2034 (USD Billion)
- 42. Global Biologics and Biosimilars Market by Retail Pharmacies, 2026 - 2034 (USD Billion)
- 43. Global Biologics and Biosimilars Market by Hospital Pharmacies, 2026 - 2034 (USD Billion)
- 44. Global Biologics and Biosimilars Market by Online Pharmacies, 2026 - 2034 (USD Billion)
- 45. Global Biologics and Biosimilars Market by Specialty Pharmacies, 2026 - 2034 (USD Billion)
- 46. Global Biologics and Biosimilars Market share, by Region, 2026 and 2034
- 47. North America Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 48. Europe Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 49. Asia Pacific Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 50. Latin America Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
- 51. The Middle-East and Africa Biologics and Biosimilars Market, 2026 - 2034 (USD Billion)
Table Of Tables
- 1. Global Biologics and Biosimilars Market: Snapshot
- 2. Drivers of the Biologics and Biosimilars Market: impact analysis
- 3. North America Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 4. North America Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 5. North America Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 6. North America Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 7. North America Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 8. U.S. Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 9. U.S. Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 10. U.S. Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 11. U.S. Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 12. U.S. Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 13. Canada Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 14. Canada Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 15. Canada Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 16. Canada Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 17. Canada Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 18. Europe Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 19. Europe Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 20. Europe Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 21. Europe Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 22. Europe Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 23. Germany Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 24. Germany Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 25. Germany Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 26. Germany Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 27. Germany Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 28. France Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 29. France Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 30. France Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 31. France Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 32. France Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 33. U.K. Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 34. U.K. Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 35. U.K. Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 36. U.K. Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 37. U.K. Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 38. Italy Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 39. Italy Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 40. Italy Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 41. Italy Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 42. Italy Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 43. Spain Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 44. Spain Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 45. Spain Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 46. Spain Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 47. Spain Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 48. Rest of Europe Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 49. Rest of Europe Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 50. Rest of Europe Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 51. Rest of Europe Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 52. Rest of Europe Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 53. Asia Pacific Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 54. Asia Pacific Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 55. Asia Pacific Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 56. Asia Pacific Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 57. Asia Pacific Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 58. China Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 59. China Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 60. China Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 61. China Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 62. China Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 63. Japan Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 64. Japan Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 65. Japan Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 66. Japan Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 67. Japan Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 68. India Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 69. India Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 70. India Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 71. India Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 72. India Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 73. South Korea Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 74. South Korea Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 75. South Korea Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 76. South Korea Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 77. South Korea Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 78. South-East Asia Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 79. South-East Asia Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 80. South-East Asia Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 81. South-East Asia Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 82. South-East Asia Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 83. Rest of Asia Pacific Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 84. Rest of Asia Pacific Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 85. Rest of Asia Pacific Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 86. Rest of Asia Pacific Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 87. Rest of Asia Pacific Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 88. Latin America Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 89. Latin America Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 90. Latin America Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 91. Latin America Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 92. Latin America Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 93. Brazil Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 94. Brazil Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 95. Brazil Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 96. Brazil Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 97. Brazil Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 98. Mexico Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 99. Mexico Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 100. Mexico Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 101. Mexico Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 102. Mexico Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 103. Rest of Latin America Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 104. Rest of Latin America Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 105. Rest of Latin America Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 106. Rest of Latin America Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 107. Rest of Latin America Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 108. The Middle-East and Africa Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 109. The Middle-East and Africa Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 110. The Middle-East and Africa Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 111. The Middle-East and Africa Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 112. The Middle-East and Africa Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 113. GCC Countries Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 114. GCC Countries Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 115. GCC Countries Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 116. GCC Countries Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 117. GCC Countries Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 118. South Africa Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 119. South Africa Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 120. South Africa Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 121. South Africa Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 122. South Africa Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
- 123. Rest of Middle-East Africa Biologics and Biosimilars Market revenue, By Drug Class, 2026 - 2034 (USD Billion)
- 124. Rest of Middle-East Africa Biologics and Biosimilars Market revenue, By Source, 2026 - 2034 (USD Billion)
- 125. Rest of Middle-East Africa Biologics and Biosimilars Market revenue, By Application, 2026 - 2034 (USD Billion)
- 126. Rest of Middle-East Africa Biologics and Biosimilars Market revenue, By Manufacturing Type, 2026 - 2034 (USD Billion)
- 127. Rest of Middle-East Africa Biologics and Biosimilars Market revenue, By Distribution Channel, 2026 - 2034 (USD Billion)
Methodology
FrequentlyAsked Questions
Biologics are an advanced set of medicinal drugs produced from living organisms or cells.
The global biologics and biosimilars market is expected to be influenced by the rising prevalence of cancer.
According to study, the global biologics and biosimilars market size was worth around USD 527.36 billion in 2025 and is predicted to grow to around USD 1320.19 billion by 2034.
The CAGR value of the biologics and biosimilars market is expected to be around 10.77% during 2026-2034.
The global biologics and biosimilars industry will be challenged by concerns over Intellectual Property (IP) disputes, which can be complex and time-consuming.
Use of interchangeable biosimilars and simplification of development processes are the emerging trends and innovations impacting the biologics and biosimilars market.
The global biologics and biosimilars market has performed well so far and will offer similar trends in the coming years.
North America will contribute notably towards the biologics and biosimilars market value.
The global biologics and biosimilars market is led by players like Roche, Fresenius Kabi, Biocon Biologics, Johnson & Johnson, Amgen, Merck & Co., Samsung Bioepis, Pfizer, Teva Pharmaceuticals, AbbVie, Celltrion, Eli Lilly, Sanofi, Sandoz, and Biogen.
The report explores crucial aspects of the biologics and biosimilars market, including a detailed discussion of existing growth factors and restraints, while also browsing future growth opportunities and challenges that impact the market.
HappyClients
